Adding bevacizumab to niraparib extends PFS in recurrent ovarian cancer

  • Lancet Oncol

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding bevacizumab to niraparib extends PFS in patients with high-grade platinum-sensitive recurrent ovarian cancer, irrespective of homologous recombination deficiency (HRD) status or chemotherapy-free interval (CFI).

Why this matters

  • Use of standard platinum-based chemotherapy is limited by cumulative toxicity.
  • A planned phase 3 trial will compare niraparib+bevacizumab with standard treatment.

Study design

  • Multinational, phase 2 AVANOVA2/ENGOT-ov24 study of 97 patients with high-grade platinum-sensitive recurrent ovarian cancer randomly assigned to niraparib±bevacizumab.
  • Primary endpoint: PFS in the intention-to-treat population; aHRsuperiority, 0.57 after events in 62 patients.
  • Funding: Nordic Society of Gynaecological Oncology; Tesaro.

Key results

  • Median follow-up was 16.9 months.
  • Niraparib+bevacizumab significantly improved median PFS vs niraparib monotherapy in:
    • Intent-to-treat population (11.9 vs 5.5 months; aHR, 0.35; P<.0001>
    • HRD-positive (HR, 0.38; 95% CI, 0.20-0.72) and HRD-negative patients (HR, 0.40; 95% CI, 0.19-0.85).
    • Patients with CFI 6-12 months (HR, 0.29; 95% CI, 0.14-0.62) and ≥12 months (HR, 0.42; 95% CI, 0.22-0.80).
  • Grade ≥3 adverse event rate was 65% with niraparib+bevacizumab and 45% for niraparib monotherapy; most common were anemia and thrombocytopenia.
  • Any grade proteinuria and hypertension were reported more frequently with niraparib+bevacizumab.
  • No difference was observed in QoL between the 2 groups.

Limitations

  • Open-label design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit